Module 3D Endocrine - Conditions Flashcards
Give a summary of type 1 diabetes
- what is it + little bit of pathophysiology
- presentation
- long term complications
- management overview
- Type 1 diabetes is a chronic autoimmune disease —> it causes immune-mediated destruction of insulin-producing pancreatic beta cells, which results in an absolute insulin deficiency and subsequent hyperglycaemia
- Patients commonly present in childhood/adolescence with the classic triad of symptoms of hyperglycaemia: polyuria, polydipsia, and weight loss (or critically unwell with DKA)
- Long-term hyperglycaemia in T1DM can lead to many complications including macrovascular damage (eg. cardiovascular, cerebrovascular, or peripheral vascular disease) and microvascular damage (eg. nephropathy, retinopathy, and neuropathy)
- The long-term management of T1DM requires an MDT approach and treatment is with exogenous insulin administration, diet, and exercise education with an aim to achieve tight glycaemic control to minimise acute risk of DKA and chronic complications
Type 1 diabetes mellitus (T1DM) aetiology
- need to cut these questions down, only way to do this is by doing them to know what to change them to
- results from an immune-mediated destruction of insulin-producing pancreatic beta-cells –> the triggers for the autoimmune attack are not fully known but thought to be influenced by both genetic and environmental factors
.
Genetic: - thought to be linked to HLA genotypes –> HLA-DR and HLA-DQ alleles
- HLA-DQ2 genotype is sometimes seen in T1DM associated with coeliac disease
.
Environmental (thought to be): - Viral infections
- Cow’s milk ingestion
- Vitamin D deficiency
- Early introduction of cereals
Type 1 diabetes mellitus (T1DM) pathophysiology + action of insulin
- results from autoimmune destruction of the insulin-producing beta cells in the islets of Langerhans of the pancreas
.
Normal action of insulin: - Insulin is needed for cells to take in glucose from the blood –> insulin activates insulin-receptors on the membranes of insulin-responsive tisues (eg. peripheral muscle and adipose tissue), stimulating the migration of glucose transporters to the cell membrane to facilitate uptake of circulating glucose into these tissues
- In addition, insulin also stimulates glycogen synthesis, and inhibits gluconeogenesis, glycogenolysis, and lipolysis
In the absence of insulin (as in T1DM), glucose cannot be taken up by insulin-responsive tissues –> causing hyperglycaemia
.
Pathophysiological process in T1DM: - most commonly a type IV hypersensitivity autoimmune reaction
- progressive beta cell destruction also leads to dysfunction of neighbouring alpha cells which produce the counter-regulatory hormone, glucagon –> this leads to overstimulation of glucagon causing further hyperglycaemia
In T1DM, long-term hyperglycaemia causes chronic macrovascular and microvascular damage –> what is the pathophysiology behind this?
(Need to redo this card - why does this happen + can use other resources (eg. Osmosis/lectures)
- thought to be related to oxidative stress, free radical damage, sorbitol production, and glycosylation of tissues
Clinical features of T1DM
Classic triad of hyperglycaemia:
- Polyuria (excessive urination)
- Polydipsia (excessive thirst)
- Weight loss (due to dehydration)
(often accompanied by fatigue and sometimes blurred vision)
Why does T1DM present with the classic triad of symptoms?
- Polyuria and polydipsia –> due to hyperglycaemia causing osmotic diuresis in the renal tubules, leading to dehydration which stimulates thirst
- Unexplained weight loss –> due to depletion of glycogen stores and breakdown of adipose tissue as the body attempts to compensate for cellular glucose deficiency by increasing energy production from proteins and fats
- Fatigue –> results from impaired glucose utilisation within cells leading to low energy levels
T1DM investigations
First-line:
- Blood glucose testing –> fasting plasma glucose test (>7 mmol/L) OR a random plasma glucose test (>11mmol/L) on more than one occasion
- Glycated haemoglobin (HbA1c) –> provides an overview of blood sugar levels over the past 2-3 months (>48 mmol/mol or higher on two separate tests confirms diagnosis)
- Urine testing (urine dipstick) –> glucosuria and ketonuria are common findings in T1DM
.
Further investigations:
- Autoantibody testing –> can confirm T1DM, glutamic acid decarboxylase (GAD) antibodies, Islet cell cytoplasmic autoantibodies (ICA), Insulinoma-associated-2 antibodies (IA-2A), and insulin autoantibodies (IAA)
- C-peptide measurement –> C-peptide is co-released with insulin from beta cells in pancreas –> low lvls along with hyperglycaemia suggests T1DM due to beta-cell destruction
.
- Can perform routine bloods (FBC, renal function, and lipid profile) to screen for associated complications
What is the criteria for diagnosing diabetes mellitus in general? (as per WHO)
- Random plasma glucose level >11.1 mmol/L in the presence of symptoms of hyperglycaemia
OR - Fasting plasma glucose >7mmol/L
OR - Plasma glucose level >11mmol/L 2 hours after a 75g oral glucose load
OR - HbA1c >48mmol/mol (can be unreliable if pt has concurrent condition affecting RBC survival)
(If pt is asymptomatic then further tests should be done to confirm diagnosis)
Diabetes mellitus can be broadly classified into T1DM, T2DM, and gestational diabetes –> how would you go about identifying T1DM as the diagnosis
- Age –> often childhood/adolescence
- Clinical presentation –> classic triad or DKA
- Ketosis –> often present (may develop DKA which is life-threatening)
- Family hx –> 10% have relatives with T1DM/autoimmune conditions
- Autoantibodies –> presence of autoantibodies to islet cells, insulin, islet antigens (IA2 and IA2-beta), GAD, or the zinc transporter ZnT8 indicate autoimmune beta-cell destruction and are suggestive of T1DM (absence doesn’t rule out T1DM however)
- C-peptide –> low or undetectable (reflects endogenous insulin production)
Differentials for T1DM + temporary hyperglycaemia
- T2DM –> strong association with obesity, CVD risk factors, and family hx of T2DM + slower onset and older age + negative for autoantibodies
- Gestational diabetes –> onset during pregnancy, generally resolves after birth
- Maturity onset diabetes of the young (MODY) –> monogenic diabetes caused by mutations in an autosominal dominant gene + strong family hx + often absence of autoantibodies
- Latent autoimmune diabetes in adults (LADA) –> form of T1DM, positive for autoantibodies, low C-peptide, BUT presents in adults + slower onset
- Drug-induced diabetes –> hx of prolonged courses of drugs (eg. corticosteroids, tacrolismus, L-asparaginase, or antipsychotics)
.
Causes of temporary hyperglycaemia: - Critical illness (eg. sepsis)
- Drugs
- Neonatal hyperglycaemia
T1DM management
T1DM involves an MDT approach:
- HbA1c –> monitored every 3-6 months (target of <48 mmol/mol)
- Self-monitoring of blood glucose –> test at least 4 times a day (including before each meal and before bed)
- Blood glucose targets –> 5-7mmol/L on waking AND 4-7 mmol/L before meals at other times of the day
- Insulin administration (basal-bolus regimen) –> twice-daily insulin detemir or once daily insulin glargine AND rapid-acting insulin analogues injected before meals
(NICE recommend adding metformin if BMI > 25 kg/m²)
T1DM complications –> acute and chronic
Acute:
- Diabetic ketoacidosis (DKA) –> life-threatening, characterised by hyperglycaemia, ketosis, and metabolic acidosis (symptoms include polyuria, polydipsia, nausea, vomiting, abdo pain, and altered mental state)
- Hypoglycaemia –> can occur due to imbalance of insulin administration (too much insulin +/- carb intake and physical activity) –> presents with sweating, tremors, tachycardia, confusion, and maybe loc
.
Chronic:
- Nephropathy –> diabetes is leading cause of end-stage renal disease, usually develops after 10-20yrs, early detection via microalbuminuria screening is vital
- Retinopathy –> non-proliferative retinopathy may progress to proliferative retinopathy characterised by neovascularisation leading to vitreous haemorrhage or retinal detachment
- Neuropathy (peripheral neuropathy) –> tingling, numbness, or burning sensation –> autonomic neuropathy affects cardiovascular, gastrointestinal and genitourinary systems causing postural hypotension, gastroparesis or erectile dysfunction respectively
- CVD –> T1DM increases the risk of coronary artery disease, peripheral arterial disease and stroke. (cardiovascular complications are a major cause of morbidity and mortality in these patients)
(The management of these complications involves optimal glycaemic control, regular screening and early intervention to prevent progression and minimise impact on patient’s quality of life)
Summary of type 2 diabetes (T2DM)
- T2DM is a chronic metabolic disorder characterised by insulin resistance and impaired insulin secretion, leading to hyperglycemia
- The aetiology of T2DM is multifactorial (genetic and environmental) –> obesity, sedentary lifestyle, and poor diet + age, ethnicity, and smoking
- T2DM is associated with microvascular and macrovascular complications, along with diabetic foot, infections, and hyperglycemia emergencies
- Management involves blood glucose control, risk factor modification, and prevention of complications through regular screening and appropriate interventions
Aetiology of T2DM
Genetic factors:
- There is a strong genetic predisposition to T2DM –> exact details are not known
.
Environmental factors:
- Obesity (particularly visceral adiposity) –> excess adipose tissue leads to increased release of pro-inflammatory cytokines and free fatty acids, which contribute to insulin resistance
- Physical inactivity –> promotes obesity, impairs glucose uptake in skeletal muscle, and reduces insulin sensitivity
- Diet –> high caloric intake, particularly from refined carbs and saturated fats
- Age and ethnicity –> > 45yrs + black/hispanic/asians
- Other factors –> smoking, sleep disorders, and a hx of gestational diabetes or PCOS
What diet should be recommended to pts with T2DM?
Diets rich in fibre, whole grains, and unsaturated fats have been shown to reduce the risk of T2DM by improving insulin sensitivity and glucose metabolism
T2DM pathophysiology
- characterised by insulin resistance and β-cell dysfunction
1. Initial phase (insulin resistance) - diminished ability of cells in the liver, muscle tissue, and adipose tissue to respond to the action of insulin –> this leads to an increased demand for insulin production by pancreatic β-cells
2. In response to this increased demand, β-cells proliferate and increase insulin output –> this compensatory phase is marked by hyperinsulinemia but normoglycaemia as blood glucose levels are maintained within normal limits
3. However, over time and with persistent exposure to high levels of glucose and lipids (glucolipotoxicity), β-cell function deteriorates
4. The deterioration in β-cell function coupled with continued insulin resistance leads to a relative deficiency in the amount of functional insulin that can be produced –> this results in a failure to maintain normoglycaemia, leading to the onset of hyperglycaemia and the clinical manifestation of T2DM
(once hyperglycaemia is established, it further exacerbates insulin resistance and β-cell dysfunction through glucotoxicity - vicous cycle)
How is T2DM usually diagnosed?
T2DM is a silent disease and tends to be diagnosed on screening or routine investigations (asymptomatic)
- Some patients will present with symptoms (polyuria, polydipsia) and 25% of pts will already have microvascular complications at time of diagnosis (nephropathy, neuropathy, retinopathy)
Diagnosis criteria for T2DM + criteria for impaired fasting glucose (IFG)/impaired glucose tolerance (IGT)
- Random glucose OR oral glucose tolerance test (2hrs post 75g glucose load) –> >11.1 mmol/L
- In asymptomatic pts –> need to repeat test to confirm diagnosis
- Note: HbA1c may not be accurate if pt has increased red cell turnover condition
. - Impaired fasting glucose (IFG) –> fasting plasma glucose of 6.1-7 mmol/l
- Diabetes UK say people with IFG should then be offered a OGTT to rule out a diagnosis of diabetes –> OGTT value of 7.8-11.1 mmol/l + fasting plasma glucose < 7 mmol/l is defined as impaired glucose tolerance (IGT)
Maturity-Onset Diabetes of the Young (MODY) is a key differential for T2DM –> what is MODY
- MODY = a monogenic form of diabetes that is often misdiagnosed as T2DM
- MODY is characterised by an autosomal dominant inheritance pattern and typically presents before 25yrs of age –> it results from mutations in one of several genes that play a role in beta-cell function
What are the most common genes involved in MODY?
HNF1A, HNF4A, and GCK
What clinical features differentiate a diagnosis of MODY over T2DM?
- Age of onset –> before 25yrs of age
- Family hx –> strong family hx spanning 3 generations
- Phenotype –> pts often lack typical T2DM features (such as obesity and metabolic syndrome)
- C-peptide levels –> normal or elevated (indicating preserved beta-cell function)
- Antibody testing –> absence of diabetes-related autoantibodies (eg. GAD, IA2, and ZnT8)
(Note: if still suspicious of MODY then perform genetic testing –> HNF1A, HNF4A, and GCK)
Conservative management for T2DM (lifestyle)
- Diet –> encourage high fibre, low glycaemic index sources of carbohydrates + low-fat dairy products and oily fish + control intake of saturated fats and trans fatty acids
- Weight loss –> aim for 5-10% initial weight loss
HbA1c targets for T2DM patients –> how often should they be checked
- HbA1c should be checked every 3-6 months until stable, then 6 monthly
First-line management of type 2 diabetes mellitus (T2DM)
- metformin should be titrated up slowly to avoid risk of GI upset
- basically if pt has any CVD condition then give an SGLT-2 inhibitor in addition to metformin (eg. dapagliflozin)
- DPP-4 inhibitor –> eg. sitagliptin